Kangstem Biotech Signs MOU with Rokit Healthcare for Cell Therapy Development

Kangstem Biotech and Rokit Healthcare have signed a mutual research and development agreement (MOU) for the development of next-generation cell therapies. After the signing ceremony, the officials are taking a commemorative photo.

[Asia Economy Reporter Chunhee Lee] Gangstem Biotech announced on the 6th that it signed a memorandum of understanding (MOU) for mutual research and development cooperation with Rokit Healthcare on the 4th to develop next-generation cell therapies for various diseases.

Through this agreement, the two companies plan to combine Gangstem Biotech's stem cell therapy development capabilities with Rokit Healthcare's cell sheet technology and 4D bioprinting technology to actively develop new cell therapies for various biomaterials and diseases applicable in the stem cell therapy development process.

In particular, the two companies intend to develop biomaterials through Gangstem Biotech's umbilical cord blood stem cells and Rokit Healthcare's extracellular matrix (ECM) isolation technology, and based on this, conduct joint research on bioimplantable organoid differentiation and fabrication technology by integrating Gangstem Biotech's organoid technology with Rokit Healthcare's 4D bioprinting technology.

Rokit Healthcare is a regenerative treatment specialized platform company that provides customized artificial skin, cartilage, and more based on bioprinting. It offers an integrated platform encompassing bioprinters and kits for regenerative treatment implementation, as well as an AI smart learning system and telemedicine technology that systematize and automate these processes. The company possesses proprietary technology to isolate ECM from somatic cells and is also promoting the development of cell scaffolds and bioinks utilizing this technology.

Gangstem Biotech expects that organoid research, which is being developed as a new pipeline through this agreement, will become more active. The company plans to accelerate research on organoid differentiation, one of the important technologies in current organoid research, and the development of implant materials for applying fabricated organoids to the human body.

Jongcheon Na, CEO of Gangstem Biotech, stated, “Through research cooperation with Rokit Healthcare, which has excellent technology in bioprinting and biomaterial development, we believe a groundbreaking leap in the development of bioimplantable organoids, one of our next-generation main development targets, will be possible,” and added, “We will accelerate the development of treatments for intractable diseases with market competitiveness through full-scale joint research and development going forward.”

This content was produced with the assistance of AI translation services.